C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) C07K 14/705 (2006.01) G01N 33/564 (2006.01) G01N 33/566 (2006.01) G01N 33/68 (2006.01) G01N 33/86 (2006.01)
Patent
CA 2427749
Plasma EPCR has been isolated, characterized and shown to block cellular protein C activation and APC anticoagulant activity. Plasma EPCR appears to be about 43,000 daltons and circulates at approximately 100 ng/ml (98.4 ~ 27.8 ng/ml, n = 22). Plasma EPCR bound activated protein C with an affinity similar to that of recombinant soluble EPCR (Kd app approximately 30 nM), and inhibits both protein C activation on an endothelial cell line and APC anticoagulant activity in a one-stage factor Xa clotting assay. Soluble plasma EPCR appears to attenuate the membrane-bound EPCR augmentation of protein C activation and the anticoagulant function of activated protein C. Soluble EPCR has also been detected in urine. Levels of soluble EPCR can rise in inflammatory disease associated with vascular injury and appear to be correlated with inflammation and disease states associated with abnormal coagulation.
Esmon Charles T.
Kurosawa Shinichiro
Stearns-Kurosawa Deborah J.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Oklahoma Medical Research Foundation
LandOfFree
Diagnostic assays using soluble endothelial cell protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic assays using soluble endothelial cell protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic assays using soluble endothelial cell protein... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2046032